| Patient | Mary McLeod Bethune |
|---|---|
| Date of birth | 1875-07-10 |
| Identifiers | MRN HR-ML043-SYN-TD; SSN (made up) 000-43-2195 |
| Document date | 1948-03-23 |
| Author | Viola Harrington-Mbeki, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: lung function, FeNO and echocardiogram results with the pulmonology consultation. [S]
Mrs. Bethune returns two weeks after her first visit. This morning she had spirometry before and after albuterol, a diffusion test and FeNO in the pulmonary function laboratory, and an echocardiogram, and she then saw Dr. Oyelowo-Brandt. Her symptoms are unchanged: she wakes with cough and a tight chest two or three nights a week and is breathless on one flight of stairs; she has used albuterol most days. Her home blood pressure readings over the week averaged 144/84. She has heartburn two or three evenings a week and a blocked nose most days. She asks plainly whether this is asthma, her heart or her weight. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Tests this morning | Spirometry with bronchodilator response, DLCO, FeNO and transthoracic echocardiogram |
| Home blood pressure | Average 144/84 over seven days |
| Her question | Is it asthma, her heart, or her weight? |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Night cough and chest tightness two or three nights a week; breathless on one flight; wheeze with colds and dust |
| Cardiovascular | Negative | No chest pain, orthopnea needing extra pillows, ankle swelling or palpitations |
| Ears, nose, mouth, and throat | Positive | Blocked nose, postnasal drip and reduced smell |
| Gastrointestinal | Positive | Heartburn two or three evenings a week; no trouble swallowing |
| Constitutional | Negative | No fever or weight loss; weight 87.6 kg |
| Psychiatric | Negative | Determined; no low mood |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) | Two puffs every 4 hours as needed; she uses it most days | Respiratory tract route | 1947-11-03 to 1948-03-23 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 1948-03-23 to 1948-06-15 | completed | S |
| Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum | Two sprays each nostril daily | Nasal route | 1948-03-23 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray | Two sprays each nostril up to four times daily | Nasal route | 1948-03-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1948-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1948-03-23 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks | One capsule daily before breakfast | Oral route | 1948-03-23 to 1948-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1948-03-23 | Body height | 163 | cm | S |
| 1948-03-23 | Body weight | 87.6 | kg | S |
| 1948-03-23 | Body mass index (BMI) [Ratio] | 33 | kg/m2 | S |
| 1948-03-23 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1948-03-23 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1948-03-23 | Heart rate | 78 | /min | S |
| 1948-03-23 | Respiratory rate | 18 | /min | S |
| 1948-03-23 | Body temperature | 36.6 | Cel | S |
| 1948-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1948-03-23 | FEV1 --pre bronchodilation | 1.3 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Low | S |
| 1948-03-23 | FEV1 --post bronchodilation | 1.57 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Normal | S |
| 1948-03-23 | FEV1 measured/predicted | 64 | % | GLI Global race-neutral equations | Low | S |
| 1948-03-23 | FEV1/FVC | 0.64 | {ratio} | >=0.7 | Low | S |
| 1948-03-23 | FEV1/FVC --post bronchodilation | 0.72 | {ratio} | 0.70 or more after bronchodilator: no persistent airflow obstruction | Normal | S |
| 1948-03-23 | Diffusion capacity.carbon monoxide | 17.2 | mL/min/mm[Hg] | Lower limit of normal, GLI race-neutral; predicted 18.6 | Normal | S |
| 1948-03-23 | Fractional concentration of exhaled nitric oxide | 46 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | High | S |
| 1948-03-23 | Left ventricular Ejection fraction | 62 | % | 53-73% | Normal | S |
| 1948-03-23 | IgE [Units/volume] in Serum or Plasma | 210 | [IU]/mL | <=100 [IU]/mL | High | S |
| 1948-03-23 | Total score [ACT] | 14 | {score} | S |
Vital signs recorded on 1948-03-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Dignified and composed; speaks in full sentences; weight 87.6 kg; blood pressure 146/86, pulse 78; oxygen saturation 96 percent |
| Eyes | Fundoscopy: mild arteriolar narrowing; no hemorrhages or exudates |
| Nose | Swollen, pale inferior turbinates; no polyps visible by anterior rhinoscopy |
| Respiratory | Scattered expiratory wheeze on forced expiration; no crackles |
| Cardiovascular | Regular rhythm; no murmur or gallop; jugular venous pressure not raised; no edema; foot pulses present |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram booked | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit. |
| Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialist | active | confirmed | R09.81 | S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy. |
| Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight loss | active | confirmed | K21.9 | S — Synthetic comorbidity of asthma; not a claim about her real health. |
| Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about it | active | confirmed | E66.811 | S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight. |
| Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol alone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to her documented chronic asthma. |
| Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mL | active | confirmed | I11.9 | S — Synthetic finding of the modern work-up; not a claim about her real heart. |
| Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertension | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry with bronchodilator response, read with race-neutral equations; DLCO | At diagnosis, before starting controller therapy | Completed today | FEV1 1.30 L (64 percent) to 1.57 L (+270 mL, +21 percent); FEV1/FVC 0.64 to 0.72; DLCO 17.2 (92 percent) |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor response (NAEPP, conditional) | Completed today | 46 ppb, raised |
| Laboratory | Blood eosinophils and total and specific IgE (phenotyping) | At diagnosis and at severe asthma assessment | Completed today | Eosinophils 0.42 two weeks ago; total IgE 210; house dust mite specific IgE positive; cat, dog, cockroach and mold negative |
| Imaging | Echocardiogram, with BNP and chest X-ray from the first visit | To exclude heart failure when breathlessness is unexplained; for stage 2 hypertension or LVH | Completed today | Ejection fraction 62 percent; mild concentric LVH; grade 1 diastolic dysfunction; BNP 48 two weeks ago |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 14; night waking two or three times a week; albuterol most days |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Taught today with her new inhaler; demonstrated correctly |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Written plan with peak flow zones given |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | No oral corticosteroid course, emergency visit or admission in the past year |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Starting at step 3: low-dose budesonide-formoterol maintenance and reliever |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Never smoker; dust, colds, perfume and humid air; dust mite covers advised because she is sensitized |
| Examination | Comorbidities: rhinosinusitis, reflux, obesity, sleep apnea screen, mood | At diagnosis and yearly | Completed today | Nasal symptoms (ear, nose and throat referral), reflux (omeprazole), BMI 33.0; STOP-BANG 2 (low risk); PHQ-2 1 at the first visit |
| Self-management | Vaccinations | Yearly | Completed today | PCV20 today; influenza and COVID-19 vaccines due in the autumn; RSV due |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Not yet: treatment has only now started |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 146/86; home average 144/84 over seven days |
| Examination | Fundoscopic examination | Yearly in hypertension | Completed today | Mild arteriolar narrowing |
| Laboratory | Baseline hypertension tests: kidney function, potassium, glucose or A1c, lipids, urine albumin, TSH; ECG | At diagnosis, then yearly | Up to date | All drawn at the first visit: creatinine 0.92, potassium 4.1, A1c 5.9 percent, LDL 144, urine albumin-to-creatinine ratio 18, TSH 2.2; ECG with LVH by voltage |
| Self-management | Equity: race-neutral lung function interpretation and plain explanation | Every test | Completed today | Read with GLI Global equations; results explained to her in plain words |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2022;79(17):1757-1780 (PMID 35379504) (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)
Follow-up: Six-week review. Ear, nose and throat in four weeks. Follow the action plan: two extra inhalations and a call to the clinic if in the yellow zone for more than a day; emergency care in the red zone. Next scheduled visit 1948-05-04: six-week asthma review: control, inhaler technique and adherence, the ear, nose and throat result, blood pressure and reflux. [S]